Stephen Bardin joins atai Life Sciences | as a candidate for the Chief Financial Officer of News

  • Stephen Bardin will be joining the company on June 27, 2022 as a CFO candidate
  • Following the transition period, atai’s current chief financial officer, Greg Weaver, will become part-time strategic advisor

NEW YORK & BERLIN, June 18, 2022 (GLOBE NEWSWIRE) – ATAI Life Sciences NV (Nasdaq: ATAI) (“atai” or “The Company”), a clinical stage biopharmaceutical company with a vision to transform mental disorder treatment, today announced that Stephen Bardin, currently senior vice president of finance and operations for BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), will be appointed Chief Financial Officer in the third quarter of 2022.

Initially, Mr. Bardin will join the Company on June 27 as deputy chief financial officer and appointed chief financial officer and will be assisted in the transition by current chief financial officer Greg Weaver. Mr. Weaver will then assume the role of strategic advisor, which is expected to end on March 31, 2023, after two years of excellent service to the Company.

Mr. Bardin spent almost three years at BridgeBio, a biopharmaceutical company in the commercial stage with a wide variety of development programs, overseeing a wide range of financial activities and helping raise over $ 2 billion through various financial transactions. Prior to that, Mr. Bardin held finance, operations, and corporate development positions at Myovant Sciences, Inc., Halo Neuroscience, Inc. and Boston Consulting Group. He completed MBA studies at Stanford Graduate School of Business and graduated with honors from Duke University with BSE in Biomedical Development.

“Mr. Bardin’s highly relevant experience and his unique insight into our hub-and-spoke drug development model make him the perfect complement to our team. I am delighted to be joining us in our mission of pioneering the development of highly reliable mental health treatment, ”said Florian Brand, co-founder and CEO of atai. “We also express our deepest gratitude to Mr. Weaver for his contribution to building a strong financial function and for his leadership during our successful IPO. Without it, we wouldn’t be where we are today. “

“I am very proud of what we have achieved as a team in atai during my tenure in the last two years,” said Mr. Weaver. “With $ 335 million in cash as of March 31, 2022, we have built a company that is highly capitalized and uniquely positioned to succeed given its leadership position and diverse set of potentially transformative mental health treatments. I have no doubt that Mr. Bardin will be the perfect complement to the atai leadership team. “

About atai Life Sciences

atai Life Sciences is a clinical biopharmaceutical company dedicated to changing the way mental disorders are treated. Established in 2018 in response to a significant unmet need and lack of innovation in the field of mental health treatment, atai is dedicated to the sourcing, promotion and effective development of innovative therapies for treating depression, anxiety, addiction and other mental disorders.

The atai business model combines funding, technology, scientific and regulatory knowledge with an emphasis on innovative compounds, including psychedelic therapy and other drugs with varying safety profiles and therapeutic potential. By pooling resources and best practices, atai is committed to responsibly accelerating new drug development across all of its companies to achieve clinically meaningful and lasting behavioral changes in patients with mental health conditions.

The vision of atai is to heal mental disorders so that everyone, everywhere, can lead a more fulfilling life. For more information,

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be exempt from the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 as amended (the “Securities Act”) and Section 21E of the Stock Exchange Act of 1934 r., as amended (“Act on Exchanges”). The words “believe”, “may”, “will”, “evaluate”, “continue”, “anticipate”, “intend”, “expect”, “anticipate”, “begin”, “could”, “would”, ” Design, “plan”, “potential”, “tentative”, “probable” and similar are intended to identify forward-looking statements, although not all forward-looking statements include these words. All statements in this press release that are not historical facts, including statements regarding our expectations for management changes and related schedules, our future operating results and financial condition, our business strategy and plans, and management’s plans and goals for future operations and investments are forward-looking statements. Forward-looking statements in this press release do not constitute promises or guarantees, and you should not overly rely on these forward-looking statements as they involve known and unknown risks, uncertainties and other factors, many of which are beyond our control. may cause actual results, level of business, performance or achievements to differ materially from factors expressed or implied in such forward-looking statements.

Other risk factors include important factors described in the “Risk Factors” section of our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) and our subsequent filings with the SEC that may result in actual results, results or achievements. will differ materially and unfavorably from those expressed or implied by any forward-looking statements.

Any forward-looking statements in this document are made only as of the date of this press release and should not be relied upon as predictions of future events. Although we believe that the expectations made in the forward-looking statements are reasonable, we cannot guarantee that the future results, results or events and circumstances discussed in the forward-looking statements will be achieved or will occur. Except as required by applicable law, we undertake no obligation to update these forward-looking statements for any reason after the date of this press release, or to adjust these statements to reflect actual results or changed expectations.

contact with the investor

Greg Weaver
Chief Financial Officer

contact with the media

Alan Maliewski,
senior director of external affairs

Selected Leveraged Products at ATAI Life Sciences NV Registered ShsThrough knockouts, speculative investors can disproportionately participate in price movements. Simply select the leverage you want and we will show you the relevant products open to ATAI Life Sciences NV Registered Shs

The leverage must be between 2 and 20

No data

Leave a Comment